US EditionPublished • loading... • Updated
TREMFYA® (Guselkumab) Long-Term Data Show Sustained Clinical and Endoscopic Remission in Ulcerative Colitis Through 3 Years
Johnson & Johnson's 3-year data show over 80% of adults with moderate to severe ulcerative colitis achieved clinical remission with TREMFYA, supporting durable disease control.
- Johnson & Johnson announced Week 140 QUASAR LTE results showing TREMFYA maintained clinical remission of 80.8%, as the Feb. 21, 2026 press release said.
- The QUASAR program randomized Phase 2b/3 trials used IV induction at Weeks 0, 4 and 8, followed by SC maintenance regimens for adults with ulcerative colitis.
- Analysis used nonresponder-imputation and as-observed methods to assess durability of response, including 78.6% achieving histo-endoscopic mucosal improvement and 89% completing treatment through Week 140.
- Regulatorily, TREMFYA is already approved in key jurisdictions and endoscopic remission is linked to fewer flare-ups and lower steroid or surgery needs, Johnson & Johnson said.
- Some mechanistic findings are limited to in vitro studies and prescribers should check patients for infections and TB before starting TREMFYA because Dr. Laurent Peyrin‑Biroulet is listed as a paid consultant for Johnson & Johnson.
Insights by Ground AI
22 Articles
22 Articles
LoudounTimes.com+19 Reposted by 19 other sources
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease control for patients
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data
Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April. The post Johnson & Johnson stock price: JNJ heads into Monday wit…
Coverage Details
Total News Sources22
Leaning Left2Leaning Right5Center3Last UpdatedBias Distribution50% Right
Bias Distribution
- 50% of the sources lean Right
50% Right
L 20%
C 30%
R 50%
Factuality
To view factuality data please Upgrade to Premium
